SenzaGen AB represents several important values and a strong corporate philosophy. As a biotechnology company, SenzaGen AB strives for excellence in innovation and development of animal-free testing methods. The company is committed to delivering accurate and reliable testing solutions to better assess chemical substances for various industries, including cosmetics, pharmaceuticals, and chemicals. SenzaGen AB is dedicated to promoting animal welfare by replacing traditional animal testing methods with efficient, scientifically advanced alternatives. With a focus on sustainability, SenzaGen AB aims to contribute to a greener future and make a positive impact on human health and the environment.

SenzaGen AB is primarily present in Sweden and the European region.

SenzaGen AB, a leading biotech company, has achieved several significant milestones. The company successfully developed a highly innovative animal-free testing platform called GARD® (Genomic Allergen Rapid Detection), revolutionizing the field of allergy testing. SenzaGen AB's GARD® platform has received validation from regulatory authorities, making it a reliable and cost-effective alternative to animal testing in the cosmetics and chemical industries. The company has expanded its reach by partnering with international distributors, enabling global distribution and market penetration. SenzaGen AB's commitment to advancing animal-free testing and providing accurate allergy assessment solutions has garnered recognition and numerous prestigious awards in the scientific community, solidifying its position as a pioneer in the field.

SenzaGen AB is a cutting-edge biotech company based in Sweden. Founded in 2009, SenzaGen specializes in developing innovative animal-free testing methods for substances that can cause allergies. The company's unique technology, known as GARD, combines genetics and genomics to accurately predict the potential allergy-inducing properties of chemicals and cosmetic ingredients. SenzaGen's scientific expertise and commitment to ethical and sustainable practices have positioned them as a trusted leader in the field. With a strong focus on research and development, SenzaGen continues to pave the way for safer and more sustainable product testing, contributing to a healthier future for consumers and the environment.

The main competitors of SenzaGen AB in the market are typically companies that operate in the field of in vitro testing, specifically focused on providing alternative methods for evaluating the safety and efficacy of chemicals. These competitors often offer similar products and services, utilizing advanced cellular and molecular biology techniques to assess the potential harmful effects of substances. Companies like Charles River Laboratories, Epithelix, MatTek Corporation, and Organovo Holdings Inc. are some of the key players in this sector, competing directly with SenzaGen AB in the in vitro testing market.

SenzaGen AB is primarily active in the fields of biotechnology and life sciences.

SenzaGen AB operates based on a versatile testing platform called GARD, which stands for Genomic Allergen Rapid Detection. This platform uses genetic biomarkers to identify and classify potential allergens. SenzaGen prides itself on providing accurate and reliable results, revolutionizing the way allergies and sensitization are tested. By offering in vitro tests, SenzaGen aims to replace animal testing, complying with regulatory requirements while also reducing and refining the use of animals. This business model allows SenzaGen AB to contribute to the advancement of safer products, benefiting industries such as cosmetics, chemicals, and pharmaceuticals.

Det SenzaGen P/E-forhold er -11,22.

SenzaGen KUV er 2,45.

AlleAktien Kvalitetsscore for SenzaGen er 3/10.

Den forventede SenzaGen omsætning er 69,53 mio. SEK.

Den forventede SenzaGen indtjening er -15,19 mio. SEK.

SenzaGen AB is a Swedish provider of innovative in vitro testing procedures that offer a reliable and ethically justifiable alternative to animal testing. The company was founded in 2010 and is based in Lund, Sweden. It specializes in the development and commercialization of tests that can predict the effects of chemicals on human health. The business model of SenzaGen is based on four main areas: 1. Development of testing procedures SenzaGen offers a wide range of in vitro testing procedures specifically developed for the identification of allergenic substances. These tests include GARD (Genomic Allergen Rapid Detection), a testing procedure that measures the specific reaction of immune cells to chemicals, thus quickly and accurately determining whether a substance is potentially allergenic. 2. Sale of testing procedures SenzaGen sells its testing procedures to global customers from various industries, such as the chemical, cosmetic, and pharmaceutical industries. These customers use the tests as part of their quality control processes or to meet specific regulatory requirements. 3. Licensing of testing procedures SenzaGen also offers licenses for its testing procedures. These licenses allow customers to conduct the tests in their own laboratories, thus providing more flexibility in the testing process. 4. Collaborations and partnerships SenzaGen collaborates with other companies to drive innovation and explore new applications for its testing procedures. An example of this is the collaboration with EpiVax, an American company specialized in predicting immunity and vaccines. SenzaGen's offering also includes a wide range of products based on various testing procedures and platforms. These products include AllergyScreen, a screening kit for identifying over 2,000 chemical allergens, and GARDpotency, a testing procedure that evaluates the potency of allergenic substances. Overall, SenzaGen's business model is focused on reducing the use of animal testing for chemical testing and promoting the development of safe and ethically justifiable products. The products and testing procedures of SenzaGen have the potential to transform the way chemicals are tested and how companies develop and manufacture their products.

SenzaGen udbetaler et udbytte på 0 SEK fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for SenzaGen, eller selskabet udbetaler ikke udbytte.

ISIN'en for SenzaGen er SE0010219626.

WKN for SenzaGen er A2DX79.

Tickeren for SenzaGen er SENZA.ST.

I løbet af de sidste 12 måneder betalte SenzaGen en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil SenzaGen sandsynligvis betale en dividende på 0 SEK.

Udbytteafkastet for SenzaGen er i øjeblikket .

SenzaGen betaler kvartalsvis udbytte. Dette uddeles i månederne .

SenzaGen betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 SEK. Dette svarer til et dividendeafkast på 0 %.

SenzaGen bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på SenzaGen fra den 21.8.2024 på 0 SEK, skulle du have haft aktien i din portefølje før ex-datoen den 21.8.2024.

Udbetalingen af det sidste udbytte blev foretaget den 21.8.2024.

I løbet af 2023 udbetalte SenzaGen 0 SEK i form af dividender.

Udbytterne fra SenzaGen udbetales i SEK.